[1]
Bhise, S.B.; Yadav, A.V.; Avachat, A.M.; Malayandi, R. Bioavailability of intranasal drug delivery system. AJP, 2008, 2(4), 201-215.
[2]
Alagusundaram, M.; Chengaiah, B.; Gnanaprakash, K.; Ramkanth, S.; Madhusudhana Chetty, C.; Dhachinamoorthi, D. Nasal drug delivery system - an overview. Int. J. Res. Pharm. Sci., 2010, 1(4), 454-465.
[3]
Mufassir, M.M.; Saifee, M.; Dehghan, M.H.; Zaheer, Z.; Khan, S.; Firoz, A.; Khan, K. Effects of solvents: Preparation and characterization of sustained release intranasal microspheres of rizatriptan benzoate. JIPBS, 2014, 1, 68-71.
[4]
Harikarnpakdee, S.; Lipipun, V.; Sutanthavibul, N.; Garnpimol, C. Spray-dried mucoadhesive microspheres: Preparation and transport through nasal cell monolayer. AAPS PharmSciTech, 2006, 7(1), E1-E10.
[5]
Chien, Y.W.; Chang, S.F. Intranasal drug delivery for systemic medications. Crit. Rev. Ther. Drug Carrier Syst., 1987, 4(2), 67-194.
[6]
Eller, N.; Kollenz, C.J.; Bauer, P.; Hitzenberger, G. The duration of antidiuretic response of two desmopressin nasal sprays. Int. J. Clin. Pharmacol. Ther., 1998, 36(9), 494-500.
[7]
Khan, A.R.; Liu, M.; Khan, M.W.; Zhai, G. Progress in brain targeting drug delivery system by nasal route. J. Control. Release, 2017, 268, 364-389.
[8]
Kublik, H.; Vidgren, M.T. Nasal delivery systems and their effect on deposition and absorption. Adv. Drug Deliv. Rev., 1998, 29(1-2), 157-177.
[9]
Inoue, D.; Tanaka, A.; Kimura, S.; Kiriyama, A.; Katsumi, H.; Yamamoto, A.; Furubayashi, T. The relationship between in vivo nasal drug clearance and in vitro nasal mucociliary clearance: Application to the prediction of nasal drug absorption. Eur. J. Pharm. Sci., 2018, 117, 21-26.
[10]
Illum, L.; Watts, P.; Fisher, A.N.; Hinchcliffe, M.; Norbury, H.; Nankervis, R.; Davis, S.S. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther., 2002, 301(1), 391-400.
[11]
Andrade, C. Intranasal drug delivery in neuropsychiatry: Focus on intranasal ketamine for refractory depression. J. Clin. Psychiatry, 2015, 76(5), 628-631.
[12]
Hermann, N. Effectiveness of live attenuated influenza vaccines and trivalent inactivated influenza vaccines against confirmed influenza in children and adolescents in Saxony-Anhalt. Gesundheitswesen, 2015, 77(7), 499-501.
[13]
Antonaci, F.; Ghiotto, N.; Wu, S.; Pucci, E.; Costa, A. Recent advances in migraine therapy. Springerplus, 2016, 5(1), 1-14.
[14]
Prajapati, S.T.; Pathak, S.P.; Thakkar, J.H.; Patel, C.N. Nanoemulsion based intranasal delivery of risperidone for nose to brain targeting. Br. J. Pharm. Res., 2015, 5(1), 6-13.
[15]
Knoester, P.D.; Jonker, D.M.; Hoeven, R.T.M.V.D.; Vermeij, T.A.C.; Edelbroek, P.M.; Brekelmans, G.J.; Haan, G.J.D. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br. J. Clin. Pharmacol., 2002, 53, 501-507.
[16]
Ugwoke, M.I.; Agu, R.U.; Verbeke, N.; Kinget, R. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev., 2005, 57(11), 1640-1665.
[17]
Vyas, T.K.; Shahiwala, A.; Marathe, S.; Misra, A. Intranasal drug delivery for brain targeting. Curr. Drug Deliv., 2005, 2(2), 165-175.
[18]
Hanson, L.R.; Frey, W.H. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. J. Psychiatry Neurosci., 2008, 9(3), S5-S15.
[19]
Harris, A.S. Review: Clinical opportunities provided by the nasal administration of peptides. J. Drug Target., 1993, 1(2), 101-116.
[20]
Duvvuri, S.; Majumdar, S.; Mitra, A.K. Drug delivery to the retina: Challenges and opportunities. EOBT, 2003, 3(1), 45-56.
[21]
Davis, S.S.; Illum, L. Absorption enhancers for nasal drug delivery. Clin. Pharmacokinet., 2003, 42(13), 1107-1128.
[22]
Huang, C.H.; Kimura, R.; Nassar, R.B.; Hussain, A. Mechanism of nasal absorption of drugs I: Physicochemical parameters influencing the rate of in situ nasal absorption of drugs in rats. J. Pharm. Sci., 1985, 74(6), 608-611.
[23]
Kumar, S.K.; Varma, M.G.; Vudaykiran, A.; Kumar, A.; Sudhakar, B. Nasal drug delivery system-an overview. IJPCS, 2012, 1(3), 1358-1368.
[24]
Sing, C.; Pardeshi, V.S.; Belgamwar, V.S. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood--brain barrier: An excellent platform for brain targeting. Expert Opin. Drug Deliv., 2013, 10(7), 957-972.
[25]
Katare, Y.K.; Piazza, J.S.; Bhandari, J.; Daya, R.P.; Akilan, K.; Simpson, M.J.; Hoare, T.; Mishra, R.K. Intranasal delivery of antipsychotic drugs. SIRS, 2017, 184, 2-13.
[26]
Ugwoke, M.I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol., 2001, 53(1), 3-22.
[27]
Samaridou, E.; Alonso, M.J. Nose-to-brain peptide delivery -The potential of nanotechnology. Bioorg. Med. Chem., 2018, 26(10), 2888-2905.
[28]
Yapar, E.A. Nasal inserts for drug delivery: An overview tropical. J. Pharm. Res., 2014, 13(3), 459-467.
[29]
Barbara, P.; Alessandro, D.; Nunzia, C.; Carta, B.; Stefano, M.; Silvia, V. Progress in drug delivery to central nervous system by pro-drug approach. Molecules, 2008, 13(5), 1035-1065.
[30]
Djupesland, P.G.; John, C.; Mahmoud, R.A. The nasal approach to delivering treatment for brain diseases: An anatomic, physiologic, and delivery technology overview. Ther. Deliv., 2014, 5(6), 709-733.
[31]
Pagar, S.; Manohar, A.S.D.; Bhanudas, S.R. A review on intranasal drug delivery system. JAPER, 2013, 3(4), 333-346.
[32]
Parvathi, M. Intranasal drug delivery to brain: An overview. IJRPC, 2012, 2(3), 889-895.
[33]
Kao, H.D.; Traboulsi, A.; Itoh, S.; Dittert, L.; Hussain, A. Enhancement of the systemic and CNS specific delivery of L-dopa by the nasal administration of its water soluble prodrugs. Pharm. Res., 2000, 17(8), 978-984.
[34]
Gizurarson, S. The effect of cilia and the mucociliary clearance on successful drug delivery. Biol. Pharm. Bull., 2015, 38, 497-506.
[35]
Ugwoke, M.I.; Verbeke, N.; Kinget, R. The biopharmaceutical aspects of nasal mucoadhesive drug delivery. J. Pharm. Pharmacol., 2001, 53(1), 3-22.
[36]
Upadhyay, S.; Parikh, A.; Joshi, A.; Upadhyay, U.M.; Chotai, N.P. Intranasal drug delivery system- A glimpse to become maestro. J. Anim. Plant Sci., 2011, 1(3), 34-44.
[37]
Pires, A.; Fortuna, A.; Alves, G.; Falcao, A. Intranasal drug delivery: How, why and what for? J. Pharm. Pharm. Sci., 2009, 12(3), 288-311.
[38]
Jadhav, K.R.; Gambhire, M.N.; Shaikh, I.M.; Kadam, V.J.; Pisal, S.S. Nasal drug delivery system-factors affecting and applications. Curr. Drug Deliv., 2007, 2, 27-38.
[39]
Dey, S.; Mahanti, B.; Mazumder, B.; Malgope, A.; Dasgupta, S. Nasal drug delivery: An approach of drug delivery through nasal route. Pharm. Sin., 2011, 2(3), 94-106.
[40]
Putheti, R.R.; Patil, M.C.; Obire, O. Nasal drug delivery in pharmaceutical
and biotechnology: Present and future e-JST, 2009, 4, 1-21.
[41]
Shaikh, M.F.; Fakir, H.S.; Shaikh, S. Mohd. M. G.; Patel H.Y.; Wedachchhiya, S.S. Intranasal route: A promising technique for brain targeting. IJARIIE, 2016, 2(1), 574-586.
[42]
Krishnamoorthya, R.; Mitra, A.K. Prodrugs for nasal drug delivery. Adv. Drug Deliv. Rev., 1998, 29(1-2), 135-146.
[43]
Cernada, A.M.; Cervera, M.F.; Cesar, J.; Rodríguez, G. Factors involved in the design of nasal delivery systems for peptides and proteins. Biotecnol. Apl., 2013, 30(2), 88-96.
[44]
Thorat, S. Formulation and product development of nasal spray: An overview sch. J. Appl. Med. Sci., 2016, 4(8D), 2976-2985.
[45]
Bhowmik, D.; Kharel, R.; Jaiswal, J.; Chiranjib, B.K.P.; Kumar, S. Innovative approaches for nasal drug delivery system and its challenges and opportunities. Ann. Biol. Res., 2010, 1(1), 21-26.
[46]
Pezron, I.; Mitra, A.K.; Duvvuri, S.; Tirucherai, S.G. Prodrug strategies in nasal drug delivery. Expert Opin. Ther. Pat., 2005, 331-340.
[47]
Kaur, H.; Singh, C.; Gupta, G.D. Nasal drug delivery. Indo. American J. Pharm. Res., 2015, 5(8), 2522-2530.
[48]
Khan, A.R.; Liu, M.; Khan, M.W.; Zhai, G. Progress in brain targeting drug delivery system by nasal route. J. Control. Release, 2017, 268, 364-389.
[49]
Dudhipala, N.; Narala, A.; Bomma, R. Recent updates in the formulation strategies to enhance the bioavailability of drugs administered via intranasal route. J. Bioequivalence Bioavailab., 2016, 204-207.
[50]
Mujawar, N.; Ghatage, S.; Navale, S.; Bhagyshree, S.; Patil, S.; Patil, S.K. Nasal drug delivery: Problem solution and its application. JCPR, 2014, 4(3), 1231-1245.
[51]
Hussein, N.R. In: Bioadhesive microparticles and liposomes of anti-
Parkinson drugs for nasal delivery; PhD thesis, University of Central
Lancashire, , 2014.
[52]
Mahdi, M.H.; Conway, B.R.; Smith, A.M. Development of mucoadhesive sprayable gellan gum fluid gels. Int. J. Pharm., 2015, 488(1), 12-19.
[53]
Chaturvedi, M. Kumar. M., Pathak. K. A review on mucoadhesive polymer used in nasal drug delivery system. JAPTR, 2011, 4, 215-222.
[54]
Rathbone, M.J.; Hadgraft, J.; Roberts, M.S. Modified-release drug delivery technology; CRC Press, 2002, pp. 234-278.
[55]
Patil, S.B.; Sawant, K.K. Mucoadhesive microspheres: A promising tool in drug delivery. Curr. Drug Deliv., 2008, 5(4), 312-318.
[56]
Gavini, E.; Rassu, G.; Ferraro, L.; Generosi, A.; Rau, J.V.; Brunetti, A.; Dalpiaz, A. Influence of chitosan glutamate on the in vivo intranasal absorption of rokitamycin from microspheres. J. Pharm. Sci., 2011, 100(4), 1488-1502.
[57]
Mahdi, M.H.; Conway, B.R.; Smith, A.M. Development of mucoadhesive sprayable gellan gum fluid gels. Int. J. Pharm., 2015, 488(1), 12-19.
[58]
Swamy, N.G.N.; Abbas, Z. Preparation and in vitro characterization of mucoadhesive polyvinyl alcohol microspheres containing amlodipine besylate for nasal administration. Indian J. Pharm. Educ., 2012, 46(1), 52-58.
[59]
Cao, S.L.; Zhang, Q.Z.; Jiang, X.G. Preparation of ion-activated in situ gel systems of scopolamine hydrobromide and evaluation of its antimotion sickness efficacy. Acta Pharmacol. Sin., 2007, 28(4), 584-590.
[60]
Dyer, A.M.; Watts, P.; Castile, J.; Jabbal-Gill, I.; Nankervis, R.; Smith, A.; Illum, L. Nasal delivery of insulin using novel chitosan based formulations: A comparative study in two animal models between simple chitosan formulations and chitosan nanoparticles. Pharm. Res., 2002, 19, 998-1008.
[61]
Ozsoy, Y.; Gungor, S.; Cevher, E. Nasal delivery of high molecular weight drugs. Molecules, 2000, 14(9), 3754-3779.
[62]
Sworn, G.; Sanderson, G.R.; Gibson, W. Gellan gum fluid gels. Food Hydrocoll., 1995, 9(4), 265-271.
[63]
DOI, K. Washington, DC: U.S. Patent and Trademark Office. U.S.
Patent 6,368,616 2002.
[64]
Aikawa, K.; Matsumoto, K.; Uda, H.; Tanaka, S.; Shimamura, H.; Aramaki, Y.; Tsuchiya, S. Prolonged release of drug from o/w emulsion and residence in rat nasal cavity. Pharm. Dev. Technol., 1998, 3(4), 461-469.
[65]
Merkus, F.W.H.M.; Schipper, N.G.M.; Hermens, W.A.J.J.; Romeijn, S.G.; Verhoef, J.C. Absorption enhancers in nasal drug delivery: Efficacy and safety. J. Control. Release, 1993, 24(1), 201-208.
[66]
Klang, V.; Schwarz, J.C.; Valenta, C. Nanoemulsions in dermal drug delivery. In: Percutaneous Penetration Enhancers Chemical Methods in Penetration Enhancement; Dragicevic, N.; Maibach, H., Eds.; , 2015; pp. 255-266.
[67]
Merkus, F.W.H.M.; Schipper, N.G.M.; Hermens, W.A.J.J.; Romeijn, S.G.; Verhoef, J.C. Absorption enhancers in nasal drug delivery: Efficacy and safety. J. Control. Release, 1993, 24(1), 201-208.
[68]
Law, S.L.; Shih, C.L. Characterization of calcitonincontaining liposome formulations for intranasal delivery. J. Microencapsul., 2001, 18(2), 211-221.
[69]
Law, S.L.; Huang, K.J.; Chou, H.Y. Preparation of desmopressin-containing liposomes for intranasal delivery. J. Control. Release, 2001, 70(3), 375-382.
[70]
Muramatsu, M.; Sankaranand, V.S.; Anant, S.; Sugai, M.; Kinoshita, K.; Davidson, N.; Honjo, T. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J. Biol. Chem., 1999, 274(26), 18470-18476.
[71]
Nagai, K.; Thogersen, H.C. Generation of beta-globin by sequence specific disteolysis of a hybrid protein produced in E. coli. Nature, 1984, 308, 810-812.
[72]
Callens, C.; Remon, J.P. Evaluation of starch- maltodextrin-Carbopol 974 P mixtures for the nasal delivery of insulin in rabbits. J. Control. Release, 2000, 66(2), 215-220.
[73]
Teshima, D.; Yamauchi, A.; Makino, K.; Kataoka, Y.; Arita, Y.; Nawata, H.; Oishi, R. Nasal glucagon delivery using microcrystalline cellulose in healthy volunteers. Int. J. Pharm., 2002, 233(1), 61-66.
[74]
Ugwoke, M.I.; Sam, E.; Van Den Mooter, G.; Verbeke, N.; Kinget, R. Nasal mucoadhesive delivery systems of the anti-parkinsonian drug, apomorphine: Influence of drug-loading on in vitro and in vivo release in rabbits. Int. J. Pharm., 1999, 181(1), 125-138.
[75]
Illum, L.H.H.O.N.; Jørgensen, H.; Bisgaard, H.; Krogsgaard, O.; Rossing, N. Bioadhesive microspheres as a potential nasal drug delivery system. Int. J. Pharm., 1987, 39(3), 189-199.
[76]
Bjork, E.; Edman, P. Degradable starch microspheres as a nasal delivery system for insulin. Int. J. Pharmaceutic, 1999, 47(1-3), 233-238.
[77]
Pereswetoff-Morath, L. Microspheres as nasal drug delivery systems. Adv. Drug Deliv. Rev., 1998, 29(1), 185-194.
[78]
Krauland, A.H.; Guggi, D.; Bernkop-Schnürch, A. Thiolated chitosan microparticles: A vehicle for nasal peptide drug delivery. Int. J. Pharm., 2006, 307(2), 270-277.
[79]
Vindru, J.; Gowda, D.V.; Gupta, A. Recent advancements and novel approach through nasal delivery systems- A Review. IJPPT, 2016, 3(3), 20-32.
[80]
Zaman, M.; Chandrudu, S.; Toth, I. Strategies for intranasal delivery of vaccines. Drug Deliv. Transl. Res., 2013, 3(1), 100-109.
[81]
Galgatte, U.C.; Kumbhar, A.B.; Chaudhari, P.D. Development of insitu gel for nasal delivery: Design, optimization, in vitro and invivo evaluation. Drug Deliv., 2014, 21(1), 62-73.
[82]
Patil, S.K.; Dhage, A.N.; Patil, S.V.; Patil, S.S. Effect of different mucoadhesive polymers on release of ondansetron HCl from intranasal mucoadhesive in situ gel. IRJPBS, 2015, 2(2), 41-58.
[83]
Ban, M.M.; Chakote, V.R.; Dhembre, G.N.; Rajguru, J.R.; Joshi, D.A. In-situ gel for nasal drug delivery. IJDR, 2018, 8(2), 18763-18769.
[84]
Kashid, V.; Nikam, V.; Gaikwad, S.; Mahale, M.; Wagh, V.; Chaudhari, S. Nasal gel as promising mucosal drug delivery. WJPR, 2016, 5(6), 891-912.
[85]
Ampati, S.; Hanumakonda, A.; Maheshwaram, V. Formulation and evaluation of nasal insitu gel of fluoxetine hydrochloride. IAJPS, 2016, 3(6), 573-581.
[86]
Ravi, P.R.; Aditya, N.; Patil, S.; Cherians, L. Nasal in-situ gels for delivery of rasagiline mesylate: Improvement in bioavailability and brain localization. Drug Deliv., 2015, 22(7), 903-910.
[87]
Himawan, A. Mucoadhesive microemulsion as a nose-to-brain (ntb) transmucosal drug carrier. IJPRS, 2016, 5(2), 293-302.
[88]
Thakkar, H.; Patel, A.A.; Chauhan, N.P. Intranasal mucoadhesive microemulsion of mirtazapine: Pharmacokinetic and pharmacodynamic studies. Asian J. Pharm., 2013, 7(1), 36-42.
[89]
Shah, B.M.; Misra, M.; Shishoo, C.J.; Padh, H. Nose to brain microemulsion-based drug delivery system of rivastigmine: Formulation and ex-vivo characterization. Drug Deliv., 2015, 22(7), 918-930.
[90]
Ayoub, A.M.; Ibrahim, M.M.; Abdallah, M.H.; Mahdy, M.A. Intranasal microemulgel as surrogate carrier to enhance low oral bioavailability of sulpiride. Int. J. Pharm. Pharm. Sci., 2016, 8(10), 188-197.
[91]
Jha, S.K.; Dey, S.; Karki, R. Microemulsions- potential carrier for improved drug delivery. AJBPS, 2011, 1(1), 5-9.
[92]
Muneer, S.; Masood, Z.; Butt, S.; Anjum, S.; Zainab, H.; Anwar, N.; Ahmad, N. Proliposomes as pharmaceutical drug delivery system: A brief review. J. Nanomed. Nanotechnol., 2017, 8(3), 448-453.
[93]
Deepthi, V.; Kavitha, A.N. Liposomal drug delivery system-a review. RGUHS J. Pharm. Sci., 2014, 4(2), 47-56.
[94]
Alsarra, I.A.; Hamed, A.Y.; Alanazi, F.K. Acyclovir liposomes for intranasal systemic delivery: Development and pharmacokinetics evaluation. Drug Deliv., 2008, 15(5), 313-321.
[95]
Tiwari, S.; Goyal, A.K.; Mishra, N.; Vaidya, B.; Mehta, A.; Dube, D.; Vyas, S.P. Liposome in situ gelling system: Novel carrier based vaccine adjuvant for intranasal delivery of recombinant protein vaccine. Procedia Vaccinol., 2009, 1, 148-163.
[96]
Nayak, U.Y.; Singh, M. Formulation and in vitro-in vivo evaluation of risperidone liposomes for brain targeting; EACPT, 2015, pp. 20-22.
[97]
Chaudhari, A.; Jadhav, K.R.; Kadam, V.J. An over view: Microspheres as a nasal drug delivery system. Int. J. Pharm. Sci. Rev. Res., 2010, 5, 34-44.
[98]
Duraivel, S.; Harish, G.; Kumar, P.B.; Bhowmik, D.; Midimalapu, S. Formulation and evaluation of ciprofloxacin microspheres for nasal drug delivery. Pharma. Innovation, 2013, 2(4), 34-39.
[99]
Gavini, E.; Rassu, G.; Ferraro, L.; Beggiato, S.; Alhalaweh, A.; Velaga, S.; Marchetti, N.; Bandiera, P.; Giunchedi, P.; Dalpiaz, A. Influence of polymeric microcarriers on the in vivo intranasal uptake of an anti-migraine drug for brain targeting. Eur. J. Pharm. Biopharm., 2013, 83(2), 174-183.
[100]
Jagtap, S.R.; Shete, A.S.J.V.J.D.R. Formulation and evaluation of particulate nasal drug delivery system for the treatment of migraine. J. Biomed. Pharm., 2017, 30(4), 345-356.
[101]
Mishra, S.D.; Singh, S.K.; Kumar, A. Development and characterization of zolmitriptan loaded thiolated chitosan nanoparticles for intranasal drug delivery. Pharma. Innovation, 2016, 5(7), 19-23.
[102]
Shelke, S.; Shahi, S.; Jalalpure, S.; Dhamecha, D. Poloxamer 407-based intranasal thermoreversible gel of zolmitriptan-loaded nanoethosomes: Formulation, optimization, evaluation and permeation studies. J. Liposome Res., 2016, 26(4), 313-323.
[103]
Winner, P.; Farkas, V.; Štillová, H.; Woodruff, B.; Liss, C.; Lillieborg, S. Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ). Headache, 2016, 6(7), 1107-1119.
[104]
Butani, S.; Shah, T.; Parmar, K.; Rajput, A. Development of rizatriptan benzoate microspheres for nose to brain targeting. Int. J. App. Pharm, 2016, 8(4), 69-74.
[105]
Nair, R.; Kumar, K.S.A.; Vishnu, K.P.; Badivaddin, T.M.; Sevukarajan, M. Preparation and characterization of rizatriptan loaded solid lipid nanoparticles. J. Biomed. Sci. Res, 2011, 3(2), 392-396.
[106]
Singh, A.; Ubrane, R.; Prasad, P.; Ramteke, S. Preparation and characterization of rizatriptan benzoate loaded solid lipid nanoparticles for brain targeting. Mater Today Proc., 2015, 2(9), 4521-4543.
[107]
Eskandari, S.; Varshosaz, J.; Minaiyan, M.; Tabbakhian, M. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: In vivo pharmacodynamic studies using rat electroshock model. Int. J. Nanomedicine, 2011, 6, 363-371.
[108]
Shelke, S.; Shahi, S.; Jalalpure, S.; Dhamecha, D.; Shengule, S. Formulation and evaluation of thermoreversible mucoadhesive in-situ gel for intranasal delivery of naratriptan hydrochloride. J. Drug Deliv. Sci. Technol., 2015, 29, 238-244.
[109]
Silberstein, S.D. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine. Expert Opin. Drug Saf., 2017, 17(1), 89-97.
[110]
Jaiswal, P.L.; Darekar, A.B.; Saudagar, R.B. A recent review on nasal microemulsion for treatment of CNS disorder. Int. J. Curr. Pharm. Res., 2017, 9(4), 5-13.
[111]
Gulati, N.; Nagaich, U.; Saraf, S.A. Intranasal delivery of chitosan nanoparticles for migraine therapy. Sci. Pharm., 2013, 81(3), 843-854.
[112]
Tepper, D.E. Nasal sprays for the treatment of migraine. Headache, 2013, 53(3), 577-578.
[113]
Marmura, M.J.; Silberstein, S.D.; Schwedt, T.J. The acute treatment of migraine in adults: The american headache society evidence assessment of migraine pharmacotherapies. Headache, 2015, 55(1), 3-20.
[114]
Mohammadkarimi, N.; Jafari, M.; Mellat, A.; Kazemi, E.; Shirali, A. Evaluation of efficacy of intra-nasal lidocaine for headache relief in patients refer to emergency department. J. Res. Med. Sci., 2014, 19(4), 1-5.
[115]
Diamond, S.; Freitag, F.; Phillips, S.; Bernstein, J.; Saper, J. Intranasal Civamide for the Acute Treatment of Migraine Headache. Cephalalgia, 2000, 20(6), 597-602.
[116]
Gooriah, R.; Nimeri, R.; Ahmed, F. Evidence-based treatments for adults with migraine. Pain Res. Treat., 2015, 2015, 629382-629395.
Download PDF Flyer